Evidence map›Paper›PMID 40242612›Full record

ReviewAmerican heart journal plus : cardiology research and practice2025

Efficacy of aficamten in obstructive hypertrophic cardiomyopathy: A systematic review and meta-analysis.

Muhammad Nabeel Saddique, Hamza Irfan, Saad Ashraf, Maria Qadri, Hammad Javaid, Sana Iftikhar, Muhammad Zain Ul Haq, Laveeza Fatima, Qasim Mehmood, Anurag Jha and 5 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in American heart journal plus : cardiology research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Muhammad Nabeel SaddiqueKing Edward Medical University, Lahore 54000, Pakistan.
Hamza IrfanShaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore 54000, Pakistan.
Saad AshrafDow University of Health Sciences, Karachi, Pakistan.
Maria QadriJinnah Sindh Medical University, Karachi, Pakistan.
Hammad JavaidKing Edward Medical University, Lahore 54000, Pakistan.
Sana IftikharShaikh Khalifa Bin Zayed Al Nahyan Medical and Dental College, Lahore 54000, Pakistan.
Muhammad Zain Ul HaqDow University of Health Sciences, Karachi, Pakistan.
Laveeza FatimaAllama Iqbal Medical College, Lahore 54000, Pakistan.
Qasim MehmoodKing Edward Medical University, Lahore 54000, Pakistan.
Anurag JhaKing Edward Medical University, Lahore 54000, Pakistan.
Saad MasoodAllama Iqbal Medical College, Lahore 54000, Pakistan.
Muhammad SafiullahKing Edward Medical University, Lahore 54000, Pakistan.
Muhammad Imaz BhattiKing Edward Medical University, Lahore 54000, Pakistan.
Sheena ShamoonRawalpindi Medical University, Rawalpindi, Pakistan.
Javed IqbalHamad Medical Corporation, Doha, Qatar.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Obstructive hypertrophic cardiomyopathy (oHCM), a morbid hereditary condition, is characterized by asymmetrical intraventricular septum enlargement, obstructing blood flow from the left ventricle outflow tract (LVOT) and lowering cardiac output. Aficamten, a novel selective, oral myosin inhibitor, has been suggested to reduce myocardial hypercontractility and decrease LVOT gradient in oHCM. Methods: A comprehensive search was conducted through PubMed, Embase, Scopus, and Cochrane databases for relevant literature from inception up to May 2024. Six studies focusing on efficacy and safety aficamten was included. Pooled outcome estimates were reported as mean difference (MD) and 95 % CI using random effect model. Statistical heterogeneity was assessed using I Results: We found a significant change of -143.23 (pg/ml) NT-proBNP [95 % CI -564.8 to 278.4, I Conclusion: We found that aficamten significantly reduced myocardial stress surrogates and functional disability parameters. The small sample sizes, diverse study designs and single-arm analysis limit our findings. More robust trials with larger sample sizes are required to establish conclusive evidence.

Indexed as

AficamtenCardiac failureMeta-analysisObstructive hypertrophic cardiomyopathy

Identifiers

PMID40242612
PMCPMC12002781

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.